Mettler Toledo (MTD)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-08
$1248.96-3.60%
Close 2026-07-08 · 1-day change
Reading MTD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MTD free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-08
Reading MTD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MTD free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a stable growth opportunity with a focus on achieving consistent earnings growth. The current thesis state is intact, supported by strong recent financial performance.
The market seems to reflect a neutral valuation, with MTD priced relatively cheap compared to its peers. There is a slight expectations gap, indicating that some level of growth is already anticipated.
Management is on track to achieve adjusted earnings per share (EPS) growth of 8% to 10% for 2026, although local currency sales growth is currently mixed. The near-term risk of missing earnings is low, but the company has a history of earnings misses that could influence sentiment.
The long-term thesis hinges on the performance of sector bellwethers like TMO, DHR, and IDXX. If these companies continue to perform well, it could provide a favorable backdrop for MTD. Conversely, any negative guidance from these peers could pose risks.
Overall, MTD's fundamentals appear solid, but the outlook is sensitive to sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement, indicating that recent financial performance remains strong. There are no current threats impacting the thesis.
as of 2026-07-08
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This will show if the company can meet its target of 4% growth for 2026. Weak growth could signal deeper issues in the market.
Confirms:Local currency sales growth for Q2 is reported at 3% or below.
Disproves:Local currency sales growth for Q2 exceeds 3%.
Why it matters: The Q2 earnings report will show how the company is doing. Investors will study the results closely.
Confirms one read:Earnings report shows strong sales and EPS growth.
Confirms the other:Earnings report shows weaker than expected sales and EPS.
Why it matters: Progress in this program is key for driving sales growth. Delays or lack of updates could indicate challenges in execution.
Confirms one read:Management shares positive news. The Spinnaker program helps boost sales.
Confirms the other:There are no updates or bad news about the Spinnaker program's progress.
Why it matters: Earnings growth is a key indicator of financial health. A miss could signal deeper issues.
Confirms:Reported earnings growth for Q2 below 6%.
Disproves:Reported earnings growth for Q2 at or above 6%.
Why it matters: Changes may show new market trends or problems inside the company. This impacts investor trust.
Confirms one read:Management raises the earnings outlook for Q2 2026. It is now above what people expected.
Confirms the other:Management lowers the earnings outlook for Q2 2026. It is now below what people expected.
Why it matters: This range indicates if the company is on track for its annual EPS growth target of 8% to 10%. Missing this range could raise concerns.
Confirms:Adjusted EPS for Q2 falls within the range of $10.70 to $10.85.
Disproves:Adjusted EPS for Q2 exceeds $10.85.
Why it matters: The adjusted EPS guidance shows strong earnings growth expectations.
Confirms:Management confirms adjusted EPS guidance in the range of $46.30 to $46.95.
Disproves:Management lowers the adjusted EPS guidance from the current range.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.